key: cord-0016358-aqkvmd05 authors: ten Cate, Hugo title: Colorectal cancer and cardiovascular disease: A thrombo-inflammatory link? date: 2021-03-26 journal: Eur J Intern Med DOI: 10.1016/j.ejim.2021.03.019 sha: 2520a95a484cc350101438161ae5fc0e3ffb11e5 doc_id: 16358 cord_uid: aqkvmd05 nan related increase in chronic inflammation [7] . In real life, a combination of acute inflammatory stimuli (such as smoking, changes in air pollution status, noise, heavy caloric intake etc) superimposed on chronic inflammatory challenges, provide the biological determinants of many multifactorial diseases. The best way to manage these inflammatory challenges is to reduce the burden of triggers, accomplished by living healthier in general; however, this is not always feasible, as in particular the environment cannot be simply optimized for many people. In epidemiological research as well as interventional studies in CVD, high sensitivity C reactive protein (hsCRP) is a key inflammation biomarker. Elevated levels of hsCRP (and also interleukin-6) are associated with increased risk of cardiovascular events independent of cholesterol and other traditional risk factors [8] . HsCRP, a marker of residual inflammatory risk, is also a useful tool to assess risk and direct medication including the use of statins and more recently anti-Il1beta therapy [8] . Chronic inflammation, characterized by detectable low levels of hsCRP, is a marker for severity of atherosclerosis, but also indicative of a higher risk of cancer, particularly lung cancer [9] . However, the association between elevated hsCRP and cancer is not consistent and absent for colorectal cancer [10] , although colon cancer is considered a disease driven and aggravated by chronic inflammation [11] . A broader scope would also include markers for thromboinflammation; the links between inflammation and hypercoagulability are well established and of pivotal significance in both CVD [12] and cancer. A simple marker that reflects thrombo-inflammation is D-dimer, a fibrin cleavage fragment [13] . Elevated D-dimer levels are predictive of venous thromboembolism but also total mortality in a broader context [14] . D-dimer levels are associated with risk of atherothrombotic events in patients with systemic atherosclerosis [15] . Elevated D-dimer levels are predictive of poor outcome in patients with solid tumors [16] . Other biomarkers of thrombo-inflammation with potential not only to detect thrombosis but also recurrence of (breast) cancer, include thrombin generation analysis [17] . In the Vienna risk score for prediction of cancer associated thrombosis (CAT), D-dimer is an important element [18] . One can imagine that a combination of different biomarkers reflecting thrombo-inflammation could be helpful for risk stratification in patients with cancer and increased risk of CVD, allowing individual optimization of preventive measures including pharmacotherapy. As discussed by Whelton and colleagues, in addition to lifestyle changes aimed at reducing the burden of inflammatory challenges (including diet induced modifications of the microbiome), specific pharmacological interventions may be considered [5] . These include prescription of acetylsalicylic acid (aspirin) and other anti-inflammatory agents, like colchicine. These agents are prescribed to reduce the risk of CVD, but may also have some antitumor effects, although the evidence is still inconsistent. Other agents, like antihypertensive drugs and statins may similarly reduce the burden of chronic inflammation, but the evidence for anti-tumor effects is weak. Anti-Il 1 beta appeared to have some protective effects against lung cancer, but not against other malignancies [19] . Considering (thrombo) inflammation as a leading mechanism in CVD and cancer: can one imagine a single pharmacological approach to dampen its impact on these complex diseases? The simple answer is "no". The presented summary of data [5] does not reveal any major impact of agents that potentially target both atherosclerosis and cancer in all subjects. The same sobering conclusion was obtained regarding attempts to cure cancer with anticoagulant therapy. While animal studies provided strong evidence for antitumor effects of diverse anticoagulants, but in particular (low molecular weight) heparins, studies with these agents failed to reduce cancer burden in patients with solid tumors [20] . Newer strategies may include non-anticoagulant heparins, amongst other compounds, for their inhibitory potential against heparinase, a naturally occurring enzyme that degrades glycosaminoglycans and may thus facilitate tumor growth and metastasis [21] . Nonanticoagulant heparins are probably safer with regard to bleeding complications, a major side effect of all current antithrombotic agents. Theoretically, novel antithrombotic agents that target coagulation or platelets and lack substantial impact on hemostasis (ie bleeding risk; [22] ) may be of interest both for preventing thrombosis in patients with cancer and perhaps by modifying the risks of atherosclerosis. A recently introduced combined antithrombotic regimen, comprising of the factor Xa inhibitor rivaroxaban and aspirin, successfully reduced cardiovascular mortality, albeit at a price of bleeding complications [23] . Combining anti-inflammatory and safer antithrombotic agents could become a feasible strategy to reduce thrombo-inflammatory burden in the future. Whereas cancer used to be an ominous diagnosis, several decades ago, the chances of survival have substantially increased and fortunately, in many cases, cancer can be cured or reversed to a manageable, chronic condition. This brings along new challenges as cancer and its treatment put a burden on the cardiovascular system, with increased cardiovascular morbidity and mortality. Survivors of cancer therefore require extra attention for CV risk factors, even more so as cancer occurs more often in individuals with a suboptimal lifestyle, being exposed to risk factors like smoking, poor diet and overweight. A way forward requires more precise individual characterization of patients, in order to find the best management of CVD; precision medicine will become important, like it is increasingly in cancer treatment. This strategy will ultimately need to make smart use of data from epigenetics, transcriptomics and proteomics analyses to characterize relevant pathways and networks for individual patient endotyping, in relation to outcomes. HtC received research support from Bayer and Pfizer and is consultant for Aleveron and stockholder for Coagulation Profile. Lifestyle factors in the prevention of COVID-19 Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study Reduction of environmental pollutants for prevention of cardiovascular disease: it's time to act Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease Shared risk factors in cardiovascular disease and cancer Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease. Front Cardiovasc Med The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study C-reactive protein levels are not associated with increased risk for colorectal cancer in women Role of inflammation in pathophysiology of colonic disease: an update Scientific Reviewer Committee. Thrombo-inflammation in cardiovascular disease: an expert consensus document from the third maastricht consensus conference on thrombosis Ddimer: Preanalytical, analytical, postanalytical variables, and clinical applications D-Dimer elevation and adverse outcomes D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease. a systematic review Prognostic Role of Pretreatment Plasma D-Dimer in Patients with Solid Tumors: a Systematic Review and Meta-Analysis Thrombin generation predicts early recurrence in breast cancer patients Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: a prospective study Inhibition of IL1β by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial The non-anticoagulant promise of heparin and its mimetics Non-Anticoagulant Heparins as Heparanase Inhibitors New anticoagulants: Moving beyond the direct oral anticoagulants Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease Research by the author is sponsored through grants from the Netherlands Heart Foundation (RACE-5 and CONTRAST), the Netherlands Thrombosis Foundation (Dutch Covid and Thrombosis Coalition) and REG-MED XB (consortium sponsoring the Cardiovascular Moonshot).